Related Experiment Video

Updated: Dec 8, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Overcoming Resistance to Drugs Targeting KRAS Mutation

Delong Jiao1, Shengyu Yang1

  • 1Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA 17033, USA.

Innovation (Cambridge (Mass.))
|September 17, 2020
PubMed

Insights

Targeting KRAS G12C mutations with new drugs shows promise for cancer treatment. However, overcoming drug resistance is crucial for long-term efficacy, requiring further research into resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating KRAS mutations are common in human cancers.
  • Targeting KRAS G12C mutations represents a significant advancement in cancer therapy.
  • Drug resistance to KRAS G12C inhibitors poses a clinical challenge.

Purpose of the Study:

  • To review recent advancements in understanding resistance to KRAS G12C inhibitors.
  • To provide insights into developing strategies to overcome drug resistance.
  • To guide future research in targeted cancer therapies.

Main Methods:

  • Review of current literature on KRAS G12C inhibitor resistance.
  • Analysis of genome-wide studies interrogating resistance mechanisms.
  • Synthesis of findings to inform therapeutic development.

Main Results:

  • KRAS G12C inhibitors have shown early clinical promise.
  • Drug resistance is a significant limitation to the efficacy of these therapies.
  • Understanding resistance mechanisms is key to developing effective treatments.

Conclusions:

  • Further research is needed to address and overcome drug resistance to KRAS G12C inhibitors.
  • Developing strategies to combat resistance will enhance the clinical utility of targeted KRAS therapies.
  • This review highlights the importance of continued investigation into resistance mechanisms for improved cancer treatment outcomes.
Keywords:
DRUG RESISTANCEKRAS INHIBITORONCOGENETARGETED THERAPY

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.0K